Semax 1% 3 ml. vial

Description

Semax 1% 3 ml Solution

Manufacturer

• Produced by: Institute of Molecular Genetics (IMG), Russian Academy of Sciences.
• Country of Origin: Russia

Composition

• Each 3 ml vial contains:
  • Semax peptide (synthetic ACTH(4‑10) analogue) – 1% (10 mg/ml).
  • Excipients: sterile water, methylparaben, sodium chloride (for isotonicity).

Indications

Semax is a synthetic nootropic and neuroprotective peptide indicated for:

• Acute ischemic stroke support.
• Recovery of cognitive functions post‑TBI.
• Chronic cerebrovascular insufficiency (ischemia).
• Neuroprotection during brain surgery.
• Memory, attention, concentration enhancement in mild cognitive impairments.
• Prevention of stress‑induced mental fatigue in high‑stress scenarios.

Dosage and Administration

• Route: Intranasal only (drops).
• Dosage regimens:
  • Stroke: 3–4 drops per nostril, 4–6 times daily for 10 days.
  • Cognitive impairment: 2–3 drops per nostril, 2–3 times daily for 5–14 days.
  • Mental fatigue prevention: 1–2 drops per nostril, twice daily for 3–5 days.
• Technique: Tilt head slightly back, instill evenly into both nostrils.
• Course duration: Varies between 5 and 14 days depending on indication.

Pharmacodynamics and Mechanism of Action

Semax is a modified heptapeptide (Met‑Glu‑His‑Phe‑Pro‑Gly‑Pro) derived from ACTH(4‑7). It modulates melanocortin receptors, increases BDNF and TrkB receptor expression, enhances synaptic plasticity, boosts cerebral perfusion, and activates serotonergic and dopaminergic pathways. It exerts antioxidant, anti‑inflammatory, immunomodulatory, and neurotrophic effects without hormonal side effects. For reference, see this study.

Use in Sports

Semax is increasingly used off‑label by athletes seeking cognitive edge, enhanced focus, faster mental recovery, and reduced fatigue during training or competitions. Its ability to raise BDNF levels may aid in neuroplastic adaptation under high cognitive and physical stress. While not banned by WADA, use should be monitored by sports medicine professionals.

Clinical Studies and Evidence

Preclinical studies in rat models of chronic brain ischemia demonstrated that intranasal Semax significantly improved learning, short‑ and long‑term memory, and behavioral performance. See the full publication on ResearchGate.

In a clinical study of ischemic stroke patients, Semax administered in two courses (6000 μg/day over 10 days, with a 20‑day interval) increased plasma BDNF levels and improved rehabilitation outcomes. See this source.

Contraindications

• Hypersensitivity to Semax or excipients.
• Acute psychosis or severe psychiatric disorders.
• Severe renal or hepatic impairment (use with caution).
• Children under 7 years of age (1% solution).

Precautions and Warnings

• Monitor cognitive and neurological status during treatment.
• May cause mild nasal irritation; avoid driving or machinery if dizziness occurs.
• Consult healthcare provider if combining with other nootropics or neuro‑agents.

Adverse Effects

• Local: Nasal dryness, mild irritation, burning.
• Neurological: Headache, light dizziness, occasional irritability.
• Hypersensitivity: Rare allergic reactions such as rash or itching.

Drug Interactions

• No major drug interactions reported.
• May potentiate effects of other nootropic peptides (e.g., Selank) when co‑administered.
• Seek medical consultation before combining with psychiatric or CNS medications.

Pregnancy and Lactation

Use during pregnancy and breastfeeding is not recommended due to lack of safety data. Only consider if benefits outweigh potential risks, under medical supervision.

Overdose

In case of overdose, mild symptoms such as nasal irritation or headache may occur. These effects are generally self‑limiting. Supportive measures (hydration, rest) are usually sufficient.

Storage

• Store refrigerated at 2–8 °C; do not freeze.
• Protect from direct sunlight and humidity.
• Discard within 30 days after opening.
• Keep out of reach of children.

Patient Information

Patients must be educated on correct intranasal administration technique, expected therapeutic timeline, and signs of side effects. Report any unusual symptoms promptly. Use only under the direction of a qualified healthcare provider.

Summary

Semax 1% nasal solution is a centrally acting synthetic peptide with demonstrated neuroprotective and cognitive-enhancing effects in ischemic stroke, TBI, and stress models. Its mechanism includes upregulation of BDNF, modulation of immune and neurotransmitter systems, and promotion of cerebral perfusion. Limited but consistent clinical evidence supports its use in stroke rehabilitation. Athletes may benefit from improved focus and faster recovery, though medical oversight is essential. Semax is generally well-tolerated, with minimal side effects and no known addictive potential. Use in special populations or children requires medical supervision.